RENAL CELL CARCINOMA

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…

This phase 2 trial is studying whether giving the drug sunitinib before surgery to remove a kidney can help control metastatic renal cell carcinoma. About 50 patients with kidney cancer that has spread will take sunitinib for 28 days, then have the affected kidney removed. Resear…

This early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…

This study tests whether giving two drugs—nivolumab (immunotherapy) and cabozantinib (targeted therapy)—before removing the kidney can make all visible cancer disappear in people with advanced kidney cancer that has spread. About 38 adults with metastatic renal cell carcinoma wil…

This early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This study tests a combination of two drugs, nivolumab and axitinib, in people with advanced kidney cancer. The goal is to find the safest dose and see how well the drugs shrink tumors. About 98 participants will take part, including those who have had prior treatment and those w…

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This study is testing a new combination of two immunotherapy drugs (BGB-A445 and tislelizumab) in about 113 people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the combo can shrink tumors and how safe it is. Participants must have already t…

This study tests whether combining newer immunotherapy drugs with a standard targeted therapy (axitinib) can safely control advanced kidney cancer. About 199 adults with untreated, advanced clear-cell renal cell carcinoma will receive one of three drug combinations. The main goal…

This early-phase study tests a new immune therapy for people with advanced kidney or bladder cancer. Researchers take a person's own natural killer cells, train them in the lab to better recognize cancer, and give them back along with a protein that boosts immune activity. The ma…

This phase 2 trial is testing whether the drug cabozantinib can shrink tumors in 22 people with advanced kidney cancer before they have surgery. The goal is to see if the drug reduces tumor size enough to improve surgical outcomes and delay cancer return. Participants take caboza…

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …

This study looks at how well surgery works for people with kidney cancer that has spread to other parts of the body. About 86 patients will have the cancer removed by a surgeon. The goal is to see if this surgery helps them live longer without the cancer coming back.

This phase 2 trial is testing a daily pill called belzutifan in 50 people with VHL disease who have kidney cancer. The goal is to see if the drug can shrink tumors. Researchers are also monitoring how long any tumor shrinkage lasts and checking for side effects.

This registry follows 750 patients with small kidney tumors who are not good candidates for surgery. They receive either cryotherapy (freezing) or radiofrequency ablation (heating) to destroy the tumor. Researchers will track survival, kidney function, and complications over time…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …

This study tests a device called GPX that blocks blood flow to tumors or other targeted areas. About 114 adults with conditions like kidney tumors or bone tumors will receive the treatment. The goal is to see if the device is safe and works well at reaching and blocking small blo…

This early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer…

This study planned to test a material called PuraBond that helps stop bleeding during robotic surgery for kidney cancer. The goal was to see if it works safely and helps the kidney heal. However, the study was withdrawn before any participants were enrolled.

This phase II trial tests whether adjusting doses of two drugs—pembrolizumab (Keytruda) and axitinib (Inlyta)—based on tumor response can better control advanced kidney cancer. The study aims to enroll 75 adults with clear cell renal cell carcinoma that has spread. The trial is c…

This phase 2 trial is testing a radioactive drug called 177Lu-PSMA-617 (Pluvicto) in 24 people with advanced clear cell kidney cancer that shows a specific marker (PSMA). The drug is given by IV and aims to shrink tumors. Researchers are measuring how many patients respond and tr…

This study tested two drug combinations (lenvatinib plus everolimus or pembrolizumab) against the standard drug sunitinib in people with advanced kidney cancer. The goal was to see if the combinations could delay cancer growth better than sunitinib alone. About 1,069 adults with …

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This study tests a new drug combination (belzutifan plus palbociclib) against belzutifan alone in people with advanced clear-cell kidney cancer that has worsened after at least two prior treatments. The main goals are to check safety and find the best dose of palbociclib when use…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than one drug alone (nivolumab) for people with advanced kidney cancer that has not been treated before. About 437 participants with intermediate- or poor-risk disease are in…

This study tests whether combining three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow or shrink advanced kidney cancers that are not the common clear-cell type. About 60 adults with cancers like papillary or chromophobe RCC that have spread will receive the com…

This study tests giving focused radiation to a tumor clot in the main vein before surgery for kidney cancer. The goal is to see if this approach is safe and helps prevent the cancer from coming back within a year. About 25 people with newly diagnosed kidney cancer and a clot in t…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This study tests whether combining three drugs—ipilimumab, nivolumab, and ciforadenant—can better control advanced kidney cancer that has spread. About 50 adults with clear cell renal cell carcinoma who have not had prior treatment will receive the combo. The main goal is to see …

This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…

This study tests a device called PROSENSE™ that freezes kidney tumors to destroy them. It involves 120 adults with small kidney cancers (up to 5 cm). The goal is to see if the freezing completely covers the tumor and prevents it from coming back over 5 years. The approach is mini…

This study tests a precise, non-invasive radiation treatment called SABR for people with small kidney tumors that are growing. The goal is to stop tumor growth without surgery. Sixteen adults with tumors 5 cm or smaller are participating.

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This early-phase study tests a new drug called belzutifan, alone or combined with lenvatinib and pembrolizumab, in 45 Chinese participants with advanced kidney cancer that cannot be removed by surgery. The main goals are to check safety, how the drugs move through the body, and a…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…

This study tests an experimental drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds the safest dose, …

This early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…

This phase II trial tests three different immunotherapy combinations given before surgery to patients with high-risk clear cell kidney cancer. The goal is to see if these drugs can shrink the tumor and reduce the risk of the cancer returning. About 69 participants will receive ei…

This early-stage trial tests whether taking capsules containing processed stool from healthy donors can prevent severe immune-related side effects in people with advanced kidney cancer receiving a combination of two immunotherapy drugs (ipilimumab and nivolumab). The study involv…

This phase 3 trial tests whether adding the targeted drug cabozantinib to two immunotherapies (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer without their cancer growing. About 855 participants with intermediate- or poor-risk disease are randomly …

This early-phase trial tests an experimental drug called AB248, which aims to boost the body's cancer-fighting immune cells. It is given alone or with the approved immunotherapy Keytruda to adults with advanced solid tumors like lung cancer, melanoma, or kidney cancer. The main g…

This phase 2 trial is testing whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can prevent kidney cancer from coming back after surgery. About 272 people with high-risk kidney cancer will receive either the vaccine plus immunotherapy or…

This study planned to test a special PET-CT scan (68Ga-PSMA) in people newly diagnosed with advanced kidney cancer. The goal was to see if it could find small cancer spots that standard scans miss. However, the trial was withdrawn before any patients were enrolled, so no results …

This phase 2 study looks at whether people with certain cancers (non-small cell lung cancer, kidney cancer, or melanoma) prefer getting the drug pembrolizumab as a quick shot under the skin instead of a longer IV infusion. About 147 participants will try both methods and then say…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find tumors that are hard to see on CT scans. About 3,900 adults with certain cancers or growths will have their biopsy or ablation procedure done using this smart needle. The g…

This study tests whether a special type of CT scan (DCE-CT) can help doctors see if targeted therapy drugs for advanced kidney cancer are working. About 120 adults with metastatic renal cell carcinoma will get these scans before and shortly after starting treatment. The goal is t…

This study examines stored tumor samples from 15 people with kidney or bladder cancer who initially responded to immune checkpoint therapy but later developed new tumors. Researchers will compare the genetic and tissue features of the original and new tumors to understand how the…

This study explores whether having kidney cancer patients report their side effects weekly through a short survey can help doctors manage those side effects better. The surveys ask about symptoms like nausea and fatigue and are sent directly to the care team, who then follow up i…

This study tests a special PET/CT scan that uses a radioactive tracer to see if it can predict how kidney cancer patients will respond to immunotherapy. The trial involves 46 participants with either localized or advanced kidney cancer. Researchers will compare scan results with …

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…

This study was designed to find out how often people develop hidden heart damage after kidney removal for cancer. Researchers planned to measure a blood marker of heart injury in 120 patients. However, the study was withdrawn before enrolling anyone, so no results are available.

This study aims to identify the bacteria and fungi living in the urinary tract of people with calcium oxalate kidney stones or kidney cancer. Researchers will compare these microbial communities to those in healthy volunteers. The goal is to better understand how these tiny organ…